A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients with Advanced Solid Tumors

This Study is
No Longer Enrolling

Details
Age

Adult

Eligibility

Part B: Pathologically confirmed (histology or cytology) of the following cancer types: a. Cohort 1: taxane naive advanced/metastatic gastric cancer, lung cancer, head and neck cancer, or ovarian cancer b. Cohort 2: taxane naive advanced/metastatic breast cancer c. Cohort 3: taxane naive advanced/metastatic prostate cancer d. Cohort 4: advanced/metastatic breast or ovarian cancer patients who have either progressed on a taxane or have developed progressive disease within 6 months of receiving a taxane

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 21-3561

More information available at ClinicalTrials.gov: NCT04931823

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers